Related Experiment Video
Updated: Aug 5, 2026
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Advances in Pharmacological Therapy for Recurrent High-Grade Meningiomas
Ruining Bai1, Shuo Yin1, Yali Wang1
1Department of Neuro-Oncology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Current Cancer Drug Targets
|July 28, 2026
Summary
Recurrent high-grade meningiomas have limited treatment options. Targeted therapies and immunotherapies show promise, with combination strategies potentially improving outcomes for this aggressive brain tumor.
Area of Science:
- Neuro-oncology
- Pharmacology
- Immunology
Background:
- World Health Organization (WHO) grade 2 and 3 meningiomas are aggressive brain tumors with high recurrence rates.
- Effective systemic treatments for recurrent high-grade meningiomas are limited, necessitating research into novel therapeutic strategies.
Purpose of the Study:
- To systematically review the efficacy and safety of pharmacological treatments for recurrent high-grade meningioma.
- To summarize advances in conventional chemotherapy, targeted therapy, and immunotherapy for this challenging condition.
Main Methods:
- A comprehensive literature search was performed across major databases (PubMed, Embase, Web of Science, ClinicalTrials.gov).
- Studies investigating pharmacological interventions for recurrent high-grade meningioma were systematically reviewed.
Main Results:
- Conventional chemotherapy offers limited survival benefits, primarily for symptom management.
- Molecular targeted therapies, including anti-angiogenic agents and TKIs, show anti-tumor activity. Bevacizumab demonstrated promising progression-free survival (12-18 months).
- Immunotherapies, such as PD-1 inhibitors (PFS-6 up to 48%), CAR-T, oncolytic viruses, and personalized vaccines, show preliminary therapeutic potential.
Conclusions:
- Targeted therapies and immunotherapies represent promising avenues for recurrent high-grade meningioma.
- Future research should focus on molecular subtype-based treatments and combination regimens for improved patient outcomes and quality of life.
